A nonelutable low-molecular weight heparin stent coating for improved thromboresistance

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 100 B, Issue 5, 2012, Pages 1274-1282

  Zhao, Jonathon ^a   Falotico, Robert ^a   Nguyen, Thai ^b   Cheng, Yan ^a   Parker, Theodore ^b   Davé, Vipul ^a   Rogers, Campbell ^a   Riesenfeld, Johan ^c  

^a JOHNSON AND JOHNSON   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Carmeda AB ^*  (Sweden)

Author keywords

Drug eluting stent; Low molecular weight heparin; Thromboresistance

Indexed keywords

ANTITHROMBIN; BEAM SYSTEM; BINDING CAPACITIES; BOVINE BLOOD; DRUG-ELUTING STENTS; FACTOR XA; IDENTICAL COATINGS; IN-VITRO; INHIBITION ASSAYS; LOW-MOLECULAR WEIGHT HEPARINS; NANO-SCALE COATINGS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET DEPOSITION; STENT COATINGS; THROMBORESISTANCE;

ARTIFICIAL ORGANS; CHROMIUM; COATINGS; COBALT; MOLECULAR WEIGHT; POLYSACCHARIDES; SCANNING ELECTRON MICROSCOPY; SECONDARY ION MASS SPECTROMETRY; THICKNESS MEASUREMENT;

STENTS;

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CHROMIUM; COBALT; LOW MOLECULAR WEIGHT HEPARIN; NITROGEN; OXYGEN; RAPAMYCIN; SULFUR;

ANTICOAGULATION; ARTICLE; ATOM; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ELUTING STENT; ELUTION; MASS SPECTROMETRY; MATERIAL COATING; NONHUMAN; SCANNING ELECTRON MICROSCOPY; STAINING; THICKNESS; THROMBOGENESIS;

ANIMALS; BLOOD COAGULATION TESTS; BLOOD FLOW VELOCITY; CATTLE; CELLS, CULTURED; CHROMIUM ALLOYS; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MATERIALS TESTING; THROMBOSIS;

EID: 84862798524     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32692     Document Type: Article

References (35)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780. (Pubitemid 34586912)
2. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-1179. (Pubitemid 40523133)
3. Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE. Zotarolimus-eluting stents in patients with native coronary artery disease: Clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007;100 (Suppl 2):S45-S55. (Pubitemid 47576036)
4. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White R, Sudhir K, Cutlip DE, Petersen JL. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-686.
5. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202. (Pubitemid 43929240)
6. Werkum JWv, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verhengt FW, Berg JM. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-409.
7. Stephan Windecker BM. Late coronary stent thrombosis. Circulation 2007;116:1952-1965.
8. Kereiakes DJ CJ, Young JJ, Broderick TM. Thrombosis and drugeluting stents: A critical appraisal. Rev Cardiovasc Med 2004;5:9-15. (Pubitemid 38344495)
9. Gutensohn K, Beythien C, Bau J, Fenner T, Grewe P, Koester R, Padmanaban K, Kuehnl P. In vitro analyses of diamond-like carbon coated stents: Reduction of metal ion release, platelet activation, and thrombogenicity. Thrombosis Res 2000;99:577-585. (Pubitemid 30642739)
10. Gerckens U, Buellesfeld L, Horstkotte D, Mueller R, Staberock M, Selbach G, Schmidt T, Grube E. Evaluation of a tarcolimus-eluting coronary stent with nanoporous ceramic coating in treatment of native coronary artery lesions: Phase I and II of the PRESENT study. J Am Coll Cardiol 2003;41(Suppl 1):7-7.
11. Rajtar A, Kaluza QY, Hakimi D, Liu D, Tsu M, Lien M, Smith D, Clubb FJ Jr, Troczynski T. Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2006;2:113-115.
12. Lee CW, Park SJ. CILOTAX: A prospective randomized controlled trial of a stent eluting cilostazol and paclitaxel. 2009 Thursday, September 24, 2009; San Francisco, CA.
13. Kim W, Jeong MH, Kim KH, Sohn IS, Hong YJ, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, Cho DL, Kang JC. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: Reo-Pro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006;47:933-938.
14. Kushwaha M, Anderson JM, Bosworth CA, Andukuri A, Minor WP, Lancaster JR Jr, Anderson PG, Brott BC, Jun H-W. A nitric oxide releasing, self assembled peptide amphiphile matrix that mimics native endothelium for coating implantable cardiovascular devices. Biomaterials 2010;31:1502-1508.
15. Weng Y, Song Q, Zhou Y, Zhang L, Wang J, Chen J, Leng Y, Li S, Huang N. Immobilization of selenocystamine on TiO2 surfaces for in situ catalytic generation of nitric oxide and potential application in intravascular stents. Biomaterials, Forthcoming.
16. Frost MC, Reynolds MM, Meyerhoff ME. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials 2005;26:1685-1693. (Pubitemid 39575311)
17. Seifert B, Romaniuk P, Groth T. Bioresorbable, heparinized polymers for stent coating: in vitro studies on heparinization efficiency, maintenance of anticoagulant properties and improvement of stent haemocompatibility. J Mater Sci: Mater Med 1996;7:465-469. (Pubitemid 26267819)
18. Patravale VBK, Devesh M, Raval AJ, Kotadia HD, Otadia D, Managoli N, Doshi M. Coatings for implantable medical devices. US20070212386A1 2007.
19. Meng S, Liu Z, Shen L, Guo Z, Chou LL, Zhong W, Du Q, Ge J. The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 2009;30:2276-2283.
20. Lin Q, Ding X, Qiu F, Song X, Fu G, Ji J. In situ endothelialization of intravascular stents coated with an anti-CD34 antibody functionalized heparin-collagen multilayer. Biomaterials 2010;31:4017-4025.
21. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol 2000;12 (Suppl E):E14-E18; discussion E25-E28.
22. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Investig 1999;103:879-887. (Pubitemid 29152634)
23. Falotico R, Parker T, Grishaber R, Price S, Cohen S, Rogers C. NEVO™ - A new generation of sirolimus-eluting coronary stent. EuroIntervention 2009;5 (Suppl F):F88-F93.
24. Larm O LR, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983;11:161-173. (Pubitemid 14168691)
25. Patrick W. Serruys HE, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, Rutsch W, Heyndrickx G, Suryapranata H, Legrand V, Jacques Goy J, Materne P, Bonnier H, Marie-Claude M, Jean F, Jorge B, Antonio C, Eulogio G, Peter R, de Jaegere P, Marie-Angèle M. Heparin-coated palmaz-schatz stents in human coronary arteries: Early outcome of the Benestent-II pilot study. Circulation 1996;93:412-422.
26. Riesenfeld J, Rodén L. Quantitative analysis of N-sulfated, N-acetylated, and unsubstituted glucosamine amino groups in heparin and related polysaccharides. Anal Biochem 1990;188:383-389. (Pubitemid 20265187)
27. Pasche B, Elgue GOP, Riesenfeld J, Rasmuson A. Binding of antithrombin to immobilized heparin under varying flow conditions. Artif Organs 1991;15:481-491.
28. Sukavaneshvar S, Solen KA, Mohammad SF. Device induced thromboembolism in a bovine in vitro coronary stent model. ASAIO J 1998;44:M393-M396. (Pubitemid 28468862)
29. S. Sukavaneshvar KS, S. Mohammad. An in vitro model to study device-induced thrombosis and embolism: Evaluation of the efficacy of tirofiban, aspirin, and dipyridamole. Thromosis and Haemostasis 2000;83:322-326.
30. Thakur ML, Welch MJ, Heinrich Joist J, Edward Coleman R. Indium- 111 labeled platelets: Studies on preparation and evaluation of in vitro and in vivo functions. Thrombosis Res 1976;9:345-357.
31. Vipul Dave; charito Buensuceso DC, Jonathon Zhao, Robert Falotico. Endothelial attachment and proliferation studies on modified metal stent surfaces. Mater Res Soc Symp Proc 2010;1236:03.
32. Breckwoldt WL BM, Gould K, Allen M, Connolly RJ, Termin P. Modification of the thrombogenicity of a self-expanding vascular stent. Invest Surg 1991;4:269-278.
33. Chen JL, Li QL, Chen JY, Chen C, Huang N. Improving bloodcompatibility of titanium by coating collagen-heparin multilayers. Appl Surf Sci 2009;255:6894-6900.
34. Jiang J-H, Zhu L-P, Li X-L, Xu Y-Y, Zhu B-K. Surface modification of PE porous membranes based on the strong adhesion of polydopamine and covalent immobilization of heparin. J Membr Sci 2010;364:194-202.
35. Kristensen EME, Larsson R, Sánchez J, Rensmo H, Gelius U, Siegbahn H. Heparin coating durability on artificial heart valves studied by XPS and antithrombin binding capacity. Colloids Surf B: Biointerfaces 2006;49:1-7.